{
    "Trade/Device Name(s)": [
        "Nova Allegro UACR Assay",
        "Nova Allegro Analyzer"
    ],
    "Submitter Information": "Nova Biomedical Corporation",
    "510(k) Number": "K221813",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072409"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGX",
        "JIQ",
        "JQT"
    ],
    "Summary Letter Date": "November 19, 2024",
    "Summary Letter Received Date": "April 8, 2024",
    "Submission Date": "April 5, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1225",
        "862.1645",
        "862.2400"
    ],
    "Regulation Name(s)": [
        "Creatinine Test System",
        "Urinary protein or albumin (nonquantitative) test system",
        "Analyzer"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Albumin",
        "Creatinine",
        "Albumin/Creatinine ratio (UACR)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Nova Allegro Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric measurement",
        "Alkaline colorimetric",
        "Stored calibration curve"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Automated assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Nova Allegro UACR Assay and Nova Allegro Analyzer for quantitative measurement of urine albumin, creatinine, and UACR to aid early diagnosis of nephropathy",
    "Indications for Use Summary": "For quantitative determination of albumin, creatinine, and albumin/creatinine ratio in human urine to aid in the early diagnosis of nephropathy; analyzer intended for in vitro diagnostic use in clinical laboratory and near-patient settings with Nova Allegro Assays using Nova Allegro Test Cartridges",
    "fda_folder": "Clinical Chemistry"
}